Close Icon We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Products:

Pharma Consulting

Close Icon

Hot topics

Thought leadership

Research and development strategy

Close Icon

Events

Conferences 2020

Awards

Upcoming Webinars

Webinar recordings

Close Icon

Global Search Configuration

Search Site Products & Services
Close Icon

Search by Keyword

Focus
Needs

pharmaceutical companies pharma intelligence

The partner of choice for pharmaceutical companies

Bring game-changing drugs to market more efficiently. We’ll help you understand the competition to hone in on your strategies to improve healthcare and patient outcomes.

Get drugs to market faster

adevelopment partner pharma intelligence

The right drugs developed at the right time transform pharmaceutical and biotechnology companies and improve patients’ lives. But the process is long and complex, taking place in an ever-changing, intensely competitive arena.

How we help
As the trusted pharma research partner of the top 50 global pharmaceutical companies, we provide reliable, timely intelligence and insights to help you every step of the way during drug development.

We can help you:

Optimize your clinical trials
Stay ahead of the competition by fully understanding future patient needs
Tailor your portfolio and commercial strategies to market needs
Identify opportunities and overcome potential threats across your pipeline
Stay current and be prepared for market shifts
Access historical success rates, and development and regulatory durations from a large number of perspectives

Our unique strengths

Identify market opportunities

Understand where future drug and development opportunities lie with access to the industry’s leading forecasts and behind-the-headlines analysis.

Capitalize on treatment trends

Keep on top of global trends and access source information on the impact of developing technologies.

Approach reimbursement proactively

Our reimbursement analysis can assist your business planning – both at the early stages of product development and long after product launch.

View competitor activity

Get unique competitor insight with our detailed reviews of your competitors’ clinical trials and our ability to track all drugs in development.

View more
View Less

Relevant products

Biomedtracker: follow the drug development process

Track and assess key events that will impact a drug’s probability of technical success and approval.

Key benefits:

Stay up to date
Get ahead of the competition
Conference coverage

HBW Insight: Health, Beauty and Wellness

The single most comprehensive consumer healthcare information source covering regulatory, legislative, legal and commercial news across the over the counter medicines, vitamins and dietary supplements, and cosmetics industries.

Key benefits:

Get a global view
Be the first to know
Go beyond the news

Generics Bulletin

A well-respected and trusted industry source for the last 15 years, Generics Bulletin from Informa Pharma Intelligence provides in-depth news and analysis on issues that matter most to businesses across the generics, biosimilars and value-added medicines industries.

Key benefits:

Ask-the-Analyst™ Service
A powerful online platform
In-depth content coverage

View all content

Scrip

J.P. Morgan Conference Updates

By Mandy Jackson 22 Jan 2020

Updates and coverage of the 2020 J.P. Morgan Healthcare Conference in San Francisco.

View article
Scrip

O’Day Lays Out Plan For Gilead’s Continued HIV Dominance

By Joseph Haas 15 Jan 2020

Biktarvy’s powerful sales growth and the potential of a first-in-class capsid inhibitor in both prevention and heavily treatment-experienced patients are key to Gilead’s plan for staying on top in HIV.

View analysis
Scrip

Korea 2020 Outlook: Hopes Of Turnaround Amid Potential Deals, Biosimilar Launches, Biologics Law

By Jung Won Shin 15 Jan 2020

After a year full of disappointing and unexpected events, the South Korean pharma sector is hoping for a turnaround in 2020, with expected biosimilar launches in global markets, progress in drug pipelines, large IPOs and implementation of a new law on cutting-edge biologics.

Topic Clinical Trials Deal trends

View analysis
Generics Bulletin

California Plans To Create Own Generics Label

By Aidan Fry 15 Jan 2020

California’s 2020-2021 fiscal budget includes plans to work with manufacturers to establish the state’s own generics label. But industry is sceptical that the initiative will deliver the savings that the US state hopes for.

View analysis
HBW Insight

OTC Zantac And Private Label Ranitidine Numerous In FDA Recall Updates

15 Jan 2020

In addition to Sanofi, firms recalling OTC ranitidine products with documentation included in FDA's database updates through 9 January are Amneal Pharmaceuticals, Preferred Pharmaceuticals, which distributed products made by Amneal, and Granules India Ltd.

View article
HBW Insight

Bayer Harnessing Skin Microbiome In New Product Development

By Tom Gallen 15 Jan 2020

Bayer has teamed up with skin microbiome specialist Azitra to develop consumer health products for a host of conditions.

View article
HBW Insight

EU Wellness Market In 2019: The CBD Green Rush

By Tom Gallen 09 Jan 2020

An interactive timeline of HBW Insight's coverage of the blossoming European CBD market in 2019. The timeline covers the main events of the year beginning with the European Commission's decision to classify CBD as a novel food, and ending on the filing of the first application for a synthetic form of the cannabis-derived ingredient.

View infographic
HBW Insight

Steripod Bolt-on Deal Extends Perrigo Into Toothbrush And Razor Accessories

By Eileen Francis 08 Jan 2020

Perrigo's Ranir division purchased the brand, which includes a portfolio of antibacterial toothbrush protectors, children’s products and tongue cleaners, for an undisclosed amount from Bonfit America.

View article
Generics Bulletin

Biocon Biologics Gets True North Investment

By Anju Ghangurde 08 Jan 2020

Private equity group True North continues to back the Biocon group and is picking up a minority stake in Biocon Biologics in a deal that values the subsidiary at $3bn. Separately, another subsidiary, Biocon Biosphere, has also been set up as part of efforts to unlock the full potential of the business.

Topic Deal trends Strategy

View analysis
Scrip

Scrip Asks...What Does 2020 Hold For Biopharma? Part 1: Therapeutic Advances

By Eleanor Malone 08 Jan 2020

Advances in multiple scientific areas will mature into novel therapeutics, often tailored for the individual patient and increasingly curative, making biopharma an exciting place to be in 2020.

View analysis
Scrip

J.P. Morgan 2020: What To Watch For At The Industry's Biggest Meeting

By Jessica Merrill 08 Jan 2020

The J.P. Morgan Healthcare conference is being held a week later than usual, which only makes us more ready to hear what the industry's leaders have in store. Here's a preview of potential hot topics.

View analysis
Scrip

Scrip Asia 100 Report Extract

18 Dec 2019

Access Asia Pharma Intelligence expertise and hear from Pharma journalists across Asia to reveal deep regional expertise with this sample of Scrip's Asia 100 Report.

Single report
HBW Insight

'Supplement' on CBD Product Label A Bullseye For US Litigants, Says Attorney

By Eileen Francis 18 Dec 2019

Two CBD marketers warned by FDA in a recent crackdown are targeted in class action complaints alleging they made unsubstantiated health claims and mislabeled ‘illegal drug’ products as supplements. Complaints are a wake-up call to CBD wellness industry to ensure claims are substantiated, as the class action bar is on the prowl following the agency’s 15 warning letter blast in November.

View article
Generics Bulletin

Alberta Is Second Canadian Province To Switch To Biosimilars

By David Wallace 18 Dec 2019

Alberta has become the second Canadian province to announce a biosimilar switching program, following the example set by British Columbia earlier this year. The move has been welcomed by Biosimilars Canada but criticized by originator-backed body Crohn’s and Colitis Canada.

View article
HBW Insight

Reckitt Targets UK's Painful 'Tweens' With Double-Strength Nurofen

By David Ridley 18 Dec 2019

Reckitt Benckiser wants to give British parents more pain relief options for their teens and "tweens."

View article